Additional Relevant Details Preliminary data is presented from the 7 subjects treated in one parotid gland in cohorts 1, 2 and 3 of the unilateral dose escalation phase of the AQUAx study who have passed the Day 90 assessment.McMaster Global Rate of Change PRO measure results:

• 6 of the 7 participants who reached the Day 90 assessment reported their symptoms of dry mouth as better following treatment
• All 6 of these participants rated changes in xerostomia scores that were important or very important to the participant (a score of 2 or more)
• 3 participants rated the change in xerostomia symptoms with the highest level of improvement (scores of 6 or 7)
• Improvement in xerostomia symptoms persisted through 1 year in two of the patients who reached Day 360
• Participant 1-1 has just reached the 24-month assessment and the highest possible score of 7 was maintained
• Participant 2-1 reported no improvement and was the only one of the 7 participants who had no saliva production at baseline
• No participant reported a worsening of xerostomia symptoms at any time point